Global Belimumab Market, By Demographic (Adult, Pediatric), Application (Lupus Nephritis, Systemic Lupus Erythematosus, Others), Dosage Form (Injection, Powder, Lyophilized, Solution), Route of Administration (Intravenous, Subcutaneous), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2029
Market Analysis and Insights Global Belimumab Market
Belimumab market is expected to gain market growth in the forecast period of 2022-2029. Data Bridge Market Research analyses the market to account to grow at a CAGR of 3.30% in the above mentioned forecast period and is likely to reach the USD 1,319.33 million by 2029.
Belimumab is a B-lymphocyte stimulator (BLyS)-specific inhibitor that reduces B cell survival indirectly and is used to treat individuals with active systemic lupus erythematosus who have autoantibody positive disease. Belimumab is available as a powder that must be combined with a solution before being injected intravenously (into a vein) in adults and children aged 5 and up. Adults can also have belimumab in the form of a solution in an auto injector or a prefilled syringe to inject subcutaneously. Benlysta is the brand name for belimumab.
The rise in the prevalence of systemic lupus erythematosus is the major factor driving the market’s growth rate. Additionally, rising healthcare expenditure is the market driver influencing the growth rate of belimumab market. Furthermore, increasing geriatric population and upsurge in the number of clinical trial studies are the factors that will expand the belimumab market. Other factors including rise in the growing government initiatives and rising awareness will positively impact the market growth rate. Another significant factor that will cushion the growth of belimumab market is the increase in demand from various end-use industries. Also, rise in the level of disposable income and rapid urbanization will escalate the market growth rate for the mention forecast period mentioned above.
Moreover, the rise in the research and development activities and emerging new markets will provide beneficial opportunities for the belimumab market in the forecast period of 2022-2029.
However, high cost associated with product and side effects such as nausea, diarrhea, vomiting, stomach pain, dizziness, insomnia and fever, among others will belimumab hamper the market growth. Lack of awareness will further challenge the belimumab market in the forecast period mentioned above.
This belimumab market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the belimumab market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Belimumab Market Scope and Market Size
The belimumab market is segmented on the basis of demographic, application, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of demographic, the belimumab market is segmented into adult, and pediatric.
- On the basis of application, the belimumab market is segmented into lupus nephritis, systemic lupus erythematosus and others.
- On the basis of dosage form, the belimumab market is segmented into injection, powder, lyophilized, and solution. Injection segment is further sub-segmented into 120mg/vial and 400mg/vial. Solution segment is further sub-segmented into 200mg/mL.
- On the basis of route of administration, the belimumab market is segmented into intravenous, and subcutaneous.
- On the basis of end-users, the belimumab market is segmented into clinic, hospital and others.
- The belimumab market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.
Belimumab Market Country Level Analysis
Belimumab market is analyzed and market size information is provided by the country, demographic, application, dosage form, route of administration, end-users and distribution channel as referenced above.
The countries covered in the belimumab market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.
North America dominates the belimumab market due to the presence of major key players, high disposable income and well-developed healthcare infrastructure in this region. Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to the increasing research and development activities and rising government support in this region.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Belimumab market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Global Belimumab Market Share Analysis
Belimumab market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to belimumab market research.
Some of the major players operating in the belimumab market are GlaxoSmithKline plc, Pfizer Inc., AstraZeneca, TSUMURA & CO., AryoGen Pharmed, Celltrion Healthcare Co.,Ltd., FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd., and Bionovis, among others.
SKU-